Recent Updates
Recently added Catalysts

bimodal

Phase 2

End Stage Renal Disease | Small molecule | Nephrology |Baxter International Inc.|Last Updated: Aug 28, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment36
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01242904Use of a Bimodal Solution for Peritoneal DialysisPHASE2 COMPLETED 36Sep 30, 2010Feb 28, 2015Aug 28, 20171 Canada
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
net ultrafiltration efficiency in mL/g
Calculated at baseline and at the end of the 6 week intervention period

Ultrafiltration Efficiency (UFE): UFE is defined as the amount of 24 hour net Ultrafiltration (UF) obtained for every gram of carbohydrate absorbed from the dialysis solution. 1. 24-hour net ultrafiltration (in mL) is recorded automatically by the Automated Peritoneal Dialysis (APD) cycler. 2. Carbohydrate absorption is determined by calculating the difference (in grams) between the amount of glucose (measured by lab analysis) in the 24 hr peritoneal effluent, and the amount of glucose in the patient's dialysis prescription. 3. UFE will be calculated in mL/g (ie a divided by b)

Secondary Endpoints
24-hour absolute total carbohydrate absorption
Calculated at baseline and at the end of the 6 week intervention period
24-hour urine volume
Calculated at baseline and at the end of the 6 week intervention period
24-hour net sodium removal (in both peritoneal effluent and urine)
Calculated at baseline and at the end of the 6 week intervention period
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
bimodal solutionEXPERIMENTAL200 mls of 30% glucose in sterile water is added by the patient to the usual icodextrin day dwell, to create the bimodal solution intraperitoneally
icodextrinACTIVE_COMPARATOR200 mls of icodextrin is added by the patient to the usual icodextrin day dwell
Interventions
NameTypeDescription
bimodal solutionDRUG200 mL of 30% glucose infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
icodextrinDRUG200 mL of icodextrin infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Be able to provide informed consent 2. Age greater than 18 years 3. Be stable Automated Peritoneal Dialysis (APD) patients for at least 6 weeks 4. Be APD patients who; 1. Can be managed with an icodextrin long dwell AND 2. Will use 4.25% and/or a 2.5% solution for at l...

Countries:Canada
Unlock Eligibility Criteria